13F Holdings
中文EN

RFL Rafael Holdings, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1713863 · Fiscal year ends 07/31

Financial factors as of 2026-07-31 (2026Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-4.7%
TTM net income YoY-58.3%
TTM EPS YoY44.2%
Revenue 3-yr CAGR46.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,821.2%
Net margin-3,390.7%
FCF margin—
EBITDA margin-3,797.8%

Returns

ROE-36.9%
ROA-30.1%
ROIC (approx.)-61.5%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets13.3%
Debt / equity0.00x
Current ratio2.35x
Interest coverage-100.29x

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-07-31FY20252025-07-31FY20242024-07-31FY20232023-07-31FY20222022-07-31
Income statement
Revenue$874,000$917,000$637,000$279,000$410,000
Cost of revenue——$154,000—$3.50M
Gross profit——$483,000—-$3.09M
R&D expense$24.33M$12.82M$4.17M$6.31M$8.74M
SG&A expense$9.70M$13.78M$8.85M$8.93M$16.98M
Operating income-$33.41M-$29.16M-$102.63M-$15.04M-$60.48M
Interest expense$333,000$658,000$248,000—$6,000
Pretax income-$27.97M-$33.20M-$67.26M-$8.74M-$139.97M
Income tax-$13,000-$2.55M-$2.68M-$255,000—
Net income-$29.64M-$30.52M-$34.41M-$1.88M-$124.66M
EBITDA-$33.20M-$28.87M-$102.40M-$14.96M-$60.41M
EPS (basic)-0.58-1.04-1.45-0.08-6.31
EPS (diluted)-0.58-1.04-1.45-0.08-6.31
Weighted avg. shares (diluted)51.39M29.42M23.75M23.26M19.77M
Balance sheet
Cash & equivalents$22.10M$52.77M$2.67M$21.50M$26.54M
Short-term investments——$63.27M$57.71M$36.70M
Receivables$444,000$627,000$426,000$213,000$157,000
Inventory$377,000$281,000———
Current assets$25.82M$56.71M$72.50M$82.94M$108.35M
PP&E, net$1.50M$1.60M$2.12M$1.70M$1.77M
Goodwill$19.94M$19.94M$3.05M——
Intangibles$863,000$994,000$1.85M——
Total assets$83.06M$114.11M$96.83M$98.83M$118.32M
Current liabilities$10.99M$11.60M$7.51M$2.15M$21.03M
Total liabilities$11.09M$15.74M$10.57M$2.20M$21.11M
Shareholders' equity$66.31M$94.39M$82.19M$100.29M$100.52M
Cash flow statement
Operating cash flow-$29.99M-$18.92M-$7.80M-$10.89M-$26.08M
Capital expenditure$3,000$4,000$143,000—$2,000
Free cash flow-$29.99M-$18.93M-$7.95M—-$26.08M
Investing cash flow-$676,000$44.03M-$10.82M$21.21M-$63.80M
Financing cash flow-$116,000$24.83M-$179,000-$15.22M$103.86M
Depreciation & amortization$204,000$288,000$225,000$78,000$72,000
Stock-based compensation$1.39M$2.12M$2.30M$2.19M-$917,000

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.